Financials • Mineralys Therapeutics

MLYS

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	0	-19	-12	0%	L	-23	L	-11	-	-15	0	24	-15	0	0	-	-
12/2022	0	-31	-12	0%	L	-52	L	-110	-	-30	0	128	-30	0	0	-	-
12/2023	0	-85	-12	0%	L	241	L	-237	-	-86	0	203	-86	0	0	-	-
12/2024	0	-192	-123	0%	L	191	L	-198	-	-178	-0	116	-178	0	0	-	-
12/2025	0	-171	-123	0%	L	647	L	-657	-	-162	-0	591	-162	0	0	-	-

To see all financials—including updated, you must be Premium.